In part four of the Radioligands session from Uromigos Live 2024, the expert panel discusses the results of the phase 3 PEACE-3 trial, which evaluates the combination of enzalutamide with or without radium-223 in patients with metastatic castration-resistant prostate cancer. They examine key outcomes, including radiographic progression-free survival and overall survival, with the trial showing a positive impact on both metrics with nearly identical hazard ratios. The discussion touches on the evolving treatment landscape, the historical underutilization of radium-223, and whether this combination should become a new standard of care.
Uromigos Live 2024 Radioligands Part 4: PEACE-3 Results from ESMO 2024
By Brian Rini, MD, FASCO, Karen Autio, MD, Michael Morris, MD, Gary T. Smith, MD, Tanya Dorff, MD - Last Updated: October 29, 2024Related Posts
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.